Registration of the Document de base

September 5, 2018

MedinCell announces filing of its document de base with the AMF, the first step towards its planned IPO
on the regulated market of Euronext in Paris

Jacou, France, September 5, 2018, 9.00 am CEST – MedinCell, a technological pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, today announces the registration of its document de base with the Autorité des marchés financiers (“AMF”, the French Financial Markets Authority) under number I.18-062 on September 4, 2018. This is the first step towards MedinCell’s planned initial public offering (“IPO”) on the regulated market of Euronext in Paris, subject to market conditions and to receiving the AMF’s visa on the IPO prospectus. With its 110 employees, MedinCell’s objective is to significantly improve the efficiency of medical treatments. Amongst its products in development, the two most advanced – which address the treatmentof schizophrenia and postoperative orthopaedic pain – are respectively in a Phase III and Phase II clinical trial in the United States. Its seven other ongoing programmes target various therapeutic areas (depression, chronic pain, contraception, etc.) in which its BEPO® patented technology could be a game changer.

The long-acting injectable products developed by MedinCell combine active pharmaceutical ingredients present in already marketed drugs (of which the efficacy and safety profile are known and documented) with its BEPO® technology. They thus allow to combine the relatively low risk associated with the reformulation of an existing drug and the significant market potential of a new treatment. Within the framework of the development and manufacturing of its products, MedinCell collaborates with leading partners such as Teva Pharmaceuticals, AIC1, the Bill & Melinda Gates Foundation and Corbion, one of the largest global manufacturers and suppliers of biopolymers for the pharmaceutical industry.

“Our team is proud to have reached this new milestone that is a natural extension of what we have already built to take MedinCell to an advanced stage of maturity”, says Christophe Douat, Chairman of MedinCell’s Executive Board.

“We have proven our know-how, our ability to drive our projects forward and the potential of our technology, with a first product in the final phase of clinical trials prior to its marketing in the United States and a growing number of programmes in development. The compatibility of our BEPO® technology with numerous active pharmaceutical ingredients, combined with MedinCell’s expertise in formulation, enables us to envisage the broadening of our portfolio in a number of indications to address currently unmet needs in developed and emerging countries.”

BEPO®: a technology with substantial potential for long-acting injectable treatments

The proprietary BEPO® technology allows the controlled release of an active pharmaceutical ingredient over a targeted period of days, weeks or months via a simple subcutaneous injection for a systemic action, or a local injection for a targeted action. Through the injection, the BEPO® technology forms a polymer depot measuring only a few millimetres that releases the active ingredient, and totally disappears after resorption. The long-acting subcutaneous injection is an alternative to traditional – often oral – drug-taking methods. It aims to enhance treatments’ efficiency by improving adherence with medical prescriptions, a major and global issue. Indeed the World Health Organisation (WHO) estimates that one in two patients either does not begin or fail to follow their treatment and that “an improvement in adherence would have more
impact than any improvement in medical treatment” 2.
A long-acting and local injection enables the direct administration of an active pharmaceutical ingredient to the targeted area, via an intra-articular or perineural injection for example, especially in the context of a surgical procedure. The objective is to significantly reduce the quantity of drugs compared with the quantity needed if administered orally or intravenously to achieve the same effect, while limiting adverse effects.

An attractive risk-return profile related to the reformulation of existing drugs and to the
improvement of their efficiency

The products currently being developed by MedinCell use active pharmaceutical ingredients that are present in drugs already available on the market. Associated development costs and timeframes can therefore be reduced. This category of products therefore makes it possible to combine the lower risk of reformulating a known drug, versus a new molecule, with the commercial potential of a new drug thanks to the treatment’s enhanced efficiency compared to its existing forms. An extensive and diversified portfolio at an advanced stage of development and targeting major therapeutic issues
MedinCell’s portfolio currently includes three products in clinical or preclinical phases and six at the formulation research stage. Moreover, MedinCell is aiming to file at least one new IND (Investigational New Drug) per year.
MedinCell’s IPO project is intended to enable it to acquire the financial capacity needed to develop this
portfolio and, to a limited extent, to refinance part of its debt.
The three products having passed the formulation research stage and currently in development are:
• mdc-IRM, currently in a Phase III clinical trial in the United States for the treatment of schizophrenia, in partnership with the international pharmaceutical group Teva. mdc-IRM is developed from an atypical antipsychotic commonly used for the treatment of this disorder, Risperidone. Schizophrenia, indication for which adherence is a major issue, affects more than 23 million people worldwide, represents 20% of the total number of days of hospitalisation in the United States3 and an estimated  annual economic loss of between $134.4 billion and $174.3 billion4. The long-acting injectable antipsychotic market was worth $4.4 billion in 2017, with annual growth of 20%5

• mdc-CWM, currently in a Phase II clinical trial in the United States for the treatment of orthopaedic postoperative pain and inflammation, in partnership with AIC, a company specialising in orthopaedic surgery. It is a new anti-inflammatory formulation, injected intra-articularly when a knee prosthesis is implanted, that aims to considerably reduce postoperative pain and inflammation and to reduce opioid use. The efficacy of existing treatments remains limited, since 57% to 73% of operated patients express that they suffer from moderate to extreme postoperative pain6. In the United States, opioid addiction, which can follow prescribed postoperative use, has reached epidemic proportions in recent years. The Centers for Disease Control and Prevention (CDC) estimates that 91 people die every day in the United States from an opioid overdose.

• mdc-TJK, currently in preclinical development for the treatment of schizophrenia. This product, also developed in partnership with Teva, is based on a molecule different than Risperidone, and could target other patients than those of mdc-IRM.

Furthermore, MedinCell is supported by the Bill & Melinda Gates Foundation in a formulation research programme that aims to develop a 6-month injectable contraceptive that could notably facilitate women’s access to contraception in developing countries. MedinCell’s portfolio also includes five other formulation research programmes in therapeutic areas such as the central nervous system, pain and organ transplants, including a third product developed in partnership with Teva.

Availability of the document de base: MedinCell’s document de base is available on the Company’s website ( and the AMF website (, as well as free of charge upon request from the Company’s head office, 3 Rue des Frères Lumière, 34830 Jacou, France. The Company draws your attention to Chapter 4, “Risk Factors”, of the document de base registered with the AMF on September 4, 2018 under number I.18-062.

1 Arthritis Innovation Corporation: a company founded by North American clinicians and entrepreneurs 2 Adherence to Long-Term Therapies, Evidence for Actions (2003)
3 Comprehensive understanding of schizophrenia and its treatment, Maguire GA:
This document may not be published, distributed or circulated, either directly or indirectly, in the United States,
Canada, Japan or Australia

4 The Economic burden of schizophrenia in the United States in 2013, Analysis Group, Otsuka, Lundbeck LLC – 2016:
5 IMS sales data – MIDAS
6 Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post surgical pain: Results from a US national survey. Curr Med Res Opin. 2014;30(1):149-160

Forward-looking Statements
This press release may contain forward-looking statements. These statements do not constitute guarantees regarding the future performance of MedinCell. This forward-looking information covers the future outlook, growth and commercial strategy of MedinCell and is based on the analysis of future result forecasts and estimates of amounts that cannot yet be determined. By nature, forward-looking information involves risks and uncertainties, as it relates to events and depends on circumstances that may or may not occur in the future. MedinCell draws your attention to the fact that forward-looking statements provide no guarantee of future performance and that its actual financial position, results and cash flow, as well as changes in the sector in which MedinCell operates, may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. Moreover, even if MedinCell’s financial position, results, cash flow and changes in the sector in which MedinCell operates were to be in accordance with the forward-looking information contained in this document, these results or changes may not be a reliable indicator of MedinCell’s future results or developments. A description of events that could have a material adverse impact on MedinCell’s business, financial position or results, or on its ability to achieve its targets, is given in Chapter 4 “Risk Factors” of the Document de base.

No communication or other information related to this transaction or to MedinCell may be transmitted to the public in a country in which any approval or registration is required. No steps to such end have been taken or will be taken by the Company in any country in which such steps would be required (other than France). This press release does not constitute an offer or a solicitation to sell or subscribe requiring a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and Council dated 4 November 2003, as amended (the “Prospectus Directive”). With respect to the member states of the European Economic Area other than France (the “Member States”) having implemented the Prospectus Directive into law, no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in one of such Member States. As a result, the securities of MedinCell may not and will not be offered in any Member State other than France, except in accordance with the exemptions set forth in Article 3 of the Prospectus Directive. This press release must not be published, released or distributed, directly or indirectly, in the United States, Australia, Canada or Japan. This press release and the information contained herein do not constitute an offer to sell or subscribe, nor the solicitation of an order to purchase or subscribe, securities in such countries.
This press release does not constitute or form part of an offer of securities or a solicitation for purchase, subscription or sale of securities in the United States. Securities may not be offered, subscribed or sold in the United States without registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”,) and other applicable state securities law, except pursuant to an exemption from registration. MedinCell shares have not been and will not be registered under the U.S. Securities Act, and MedinCell does not intend to undertake a public offering of its securities in the United States.
This press release is not an invitation nor an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000, as amended (“FSMA”). This press release is directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (iii) persons referred to in Article 49(2)(a) to (d) of the Order (high net worth entities, non-registered associations, etc.) and (iv) other persons to whom this document may be lawfully communicated (all persons listed in (i), (ii), (iii) and (iv) above being referred to as “Relevant Persons”). The securities of MedinCell described herein are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this document or any of its contents.
The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.